Pharmaceutical pricing policy in the United States has become increasingly difficult to navigate for drug and biotech companies operating across global markets.
President Donald Trump’s ongoing deals with pharmaceutical companies, combined with Department of Health and Human Services announcements, are driving significant uncertainty across the industry.
Confidentiality surrounding the agreements is compounding the confusion, with lack of clarity on three proposed drug-price control mechanisms making the situation exceptionally hard to read.
The three proposals in question — known as GENEROUS, covering Medicaid, GLOBE, covering Medicare Part B, and GUARD, covering Medicare Part D — remain poorly understood in practical terms.
Most favoured nation drug-pricing agreements have now been announced for 26 pharmaceutical companies, representing a significant expansion of the policy’s reach.
Under threat of tariffs, these companies have agreed to reduced pricing for some Medicaid drugs, new US domestic investments, and contributions toward the Strategic Active Pharmaceutical Ingredients Reserve.
The companies have also committed to making selected drugs available through direct-to-consumer channels as part of the negotiated agreements.
Legislative paths for GENEROUS, GLOBE, and GUARD remain blocked by intra-party resistance and intensifying midterm dynamics, making durable statutory implementation unlikely in the near term.
The logic underpinning most favoured nation pricing depends on foreign price increases to rebalance global research and development funding, but most governments continue using budget-driven price suppression.
This dynamic persists despite growing demographic pressures and rising innovation costs that many analysts argue make current foreign pricing models unsustainable over the long term.
Early signals are already pointing to a retrenchment in drug launches outside the United States, with a reported 35% decline in European launches recorded since May 2025.
Reduced submissions have also been observed in markets that reference most favoured nation pricing, including Switzerland, suggesting companies are pulling back from international expansion plans.
As analyst Ed Schoonveld has noted, the implications for the viability of ex-US drug launches mean “the whole picture is best characterized as a complex chess game with invisible chess pieces.”
Recent declines in US drug prices are being claimed as a policy success by the administration, but these figures may be confounded by price erosion in the GLP-1 drug category.
Expiring three-year deals and continued policy volatility are expected to sustain investment uncertainty and access concerns well into the coming years for both manufacturers and patients.